PharmTech Drug Digest 11.20
News|Articles|November 23, 2005

GSK Study Questions Bioequivalency of Generic Cold Sore Creams

GSK Study Questions Bioequivalency of Generic Cold Sore Creams

A recent study published in the International Journal of Pharmaceutics (1) finds wide variations in the bioequivalency of several generic topical acyclovir creams used to treat recurrent Herpes labialis.

The research team members, most of whom are from GlaxoSmithKline (GSK), studied 139 generic versions of GSK’s “Zovirax” cream. Though Zovirax contains 40% propylene glycol, 111 of these creams contain less that 20% of antimicrobial preservative and solvent, according to the study data. 

To test bioavailability, the group compared the innovator cream with two generic versions that each contained 15% propylene glycol. In addition, 10 generic creams that contained <15% of this ingredient were tested in an independent laboratory. All studies were conducted on human skin and the acyclovir creams were analyzed by liquid chromatography and mass spectroscopy.

According to the research team, the innovator drug delivered 7.5-fold more acyclovir than the generic “equivalents,” which the study attributed to variations in the amount of propylene glycol.

The group’s conclusion that the marketed, generic versions of the acyclovir creams are not bioequivalent to Zovirax bolsters the notion that a drug’s formulation can influence its bioavailability, and thus its therapeutic bioequivalency. FDA requires that the innovator drug and the follow-on biologic must be therapeutically equivalent, which includes both bioequivalency and pharmaceutical equivalency (2).

References

1. L. Trottet, “Are All Aciclovir Cream Formulations Bioequivalent?” Int. J. Pharm.304 (1–2), 63–71 (2005).

2. A.K. Bansal and V. Koradia, “The Role of Reverse Engineeing in the Development of Generic Formulations,”

Pharm. Technol.

 

29

(8), 50–55 (2005).


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.